Echo Therapeutics has announced the positive results from a clinical study of its Symphony transdermal continuous glucose monitoring system in patients with type 1 and type 2 diabetes.
The feasibility study, involving 20 adult diabetecs, was designed to assess the performance of the Symphony system in an outpatient setting at a clinical research organisation.
The study confirmed that Symphony successfully monitors the broad range of blood glucose values seen in people with diabetes.
The company also plans to conduct a study in critical care patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData